JP2023531164A5 - - Google Patents
Info
- Publication number
- JP2023531164A5 JP2023531164A5 JP2022576006A JP2022576006A JP2023531164A5 JP 2023531164 A5 JP2023531164 A5 JP 2023531164A5 JP 2022576006 A JP2022576006 A JP 2022576006A JP 2022576006 A JP2022576006 A JP 2022576006A JP 2023531164 A5 JP2023531164 A5 JP 2023531164A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- item
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2006039 | 2020-06-10 | ||
| FR2006039 | 2020-06-10 | ||
| PCT/US2021/036668 WO2021252669A1 (en) | 2020-06-10 | 2021-06-09 | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531164A JP2023531164A (ja) | 2023-07-21 |
| JP2023531164A5 true JP2023531164A5 (https=) | 2024-06-17 |
Family
ID=76744954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576006A Pending JP2023531164A (ja) | 2020-06-10 | 2021-06-09 | 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230255942A1 (https=) |
| EP (1) | EP4164636A1 (https=) |
| JP (1) | JP2023531164A (https=) |
| KR (1) | KR20230038458A (https=) |
| CN (1) | CN116096373A (https=) |
| AU (1) | AU2021286565A1 (https=) |
| BR (1) | BR112022024875A2 (https=) |
| CA (1) | CA3181084A1 (https=) |
| CL (1) | CL2022003437A1 (https=) |
| CO (1) | CO2022017764A2 (https=) |
| CR (1) | CR20220624A (https=) |
| DO (1) | DOP2022000277A (https=) |
| EC (1) | ECSP22092977A (https=) |
| IL (1) | IL298901A (https=) |
| JO (1) | JOP20220329A1 (https=) |
| MA (1) | MA58993A1 (https=) |
| MX (1) | MX2022015159A (https=) |
| PE (1) | PE20240544A1 (https=) |
| PH (1) | PH12022553389A1 (https=) |
| TW (1) | TWI911229B (https=) |
| WO (1) | WO2021252669A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65839B1 (sr) | 2014-01-21 | 2024-09-30 | Neurocrine Biosciences Inc | Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| CA3201039A1 (en) * | 2023-03-13 | 2025-03-12 | Alexion Pharmaceuticals, Inc. | Formulations of danicopan and methods of use thereof |
| WO2024206769A1 (en) * | 2023-03-30 | 2024-10-03 | Neurocrine Biosciences, Inc. | Dosage regime of crinecerfont for treating congenital adrenal hyperplasia |
| TW202444356A (zh) * | 2023-05-08 | 2024-11-16 | 美商紐羅克里生物科學有限公司 | Crf拮抗劑之投與方法 |
| WO2025240605A1 (en) | 2024-05-15 | 2025-11-20 | Neurocrine Biosciences, Inc. | Combination treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2796380B3 (fr) * | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
| HUP0900267A2 (en) | 2009-04-30 | 2011-03-28 | Sanofi Aventis | Process for preparing of thiazole amines and intermediates thereof |
| RS65839B1 (sr) * | 2014-01-21 | 2024-09-30 | Neurocrine Biosciences Inc | Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije |
| WO2016065177A1 (en) * | 2014-10-22 | 2016-04-28 | The Trustees Of The University Of Pennsylvania | Method of treating depression and other stress related disorders |
| US20220023266A1 (en) * | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
-
2021
- 2021-06-09 CR CR20220624A patent/CR20220624A/es unknown
- 2021-06-09 CN CN202180055808.8A patent/CN116096373A/zh active Pending
- 2021-06-09 MX MX2022015159A patent/MX2022015159A/es unknown
- 2021-06-09 TW TW110120961A patent/TWI911229B/zh active
- 2021-06-09 PE PE2022002881A patent/PE20240544A1/es unknown
- 2021-06-09 CA CA3181084A patent/CA3181084A1/en active Pending
- 2021-06-09 WO PCT/US2021/036668 patent/WO2021252669A1/en not_active Ceased
- 2021-06-09 AU AU2021286565A patent/AU2021286565A1/en active Pending
- 2021-06-09 BR BR112022024875A patent/BR112022024875A2/pt unknown
- 2021-06-09 JP JP2022576006A patent/JP2023531164A/ja active Pending
- 2021-06-09 MA MA58993A patent/MA58993A1/fr unknown
- 2021-06-09 KR KR1020237000553A patent/KR20230038458A/ko active Pending
- 2021-06-09 PH PH1/2022/553389A patent/PH12022553389A1/en unknown
- 2021-06-09 EP EP21737274.7A patent/EP4164636A1/en active Pending
- 2021-06-09 IL IL298901A patent/IL298901A/en unknown
- 2021-06-09 US US18/009,537 patent/US20230255942A1/en active Pending
-
2022
- 2022-12-04 JO JOP/2022/0329A patent/JOP20220329A1/ar unknown
- 2022-12-05 CL CL2022003437A patent/CL2022003437A1/es unknown
- 2022-12-07 CO CONC2022/0017764A patent/CO2022017764A2/es unknown
- 2022-12-07 DO DO2022000277A patent/DOP2022000277A/es unknown
- 2022-12-07 EC ECSENADI202292977A patent/ECSP22092977A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531164A5 (https=) | ||
| TWI911229B (zh) | 用於治療先天性腎上腺增生之crf1受體拮抗劑 | |
| FI3984523T3 (fi) | Crf1-reseptorin antagonisti, lääkeformulaatioita ja niiden kiinteitä muotoja synnynnäisen lisämunuaisten liikakasvun hoitoon | |
| AU2023201703B2 (en) | Corticotropin releasing factor receptor antagonists | |
| KR100805648B1 (ko) | 복합 에스트로겐 및 메드록시프로게스테론 아세테이트와의 배합물을 사용한 호르몬 보충요법 | |
| JP2013529665A (ja) | ドロスピレノンを含む医薬組成物及び避妊用キット | |
| US20200255436A1 (en) | Corticotropin releasing factor receptor antagonists | |
| CN108025014A (zh) | 用于过重女性患者的基于屈螺酮的避孕药 | |
| US20120245552A1 (en) | Combination Therapy | |
| JPS62201819A (ja) | 免疫不全症処置剤 | |
| Battipaglia et al. | The hormonal contraceptive choice in women with polycystic ovary syndrome and metabolic syndrome | |
| JP2022000473A5 (https=) | ||
| US20210121480A1 (en) | Stable pharmaceutical compositions containing estradiol and progesterone for oral administration | |
| Żyła et al. | Progestins-a review of clinical application in gynecology | |
| JP7532328B2 (ja) | 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態 | |
| RU2024122307A (ru) | Антагонист рецептора crf1, его фармацевтические составы и твердые формы для лечения врожденной гиперплазии надпочечников | |
| RU2021119949A (ru) | Антагонист рецептора crf1, его фармацевтические составы и твердые формы для лечения врожденной гиперплазии надпочечников | |
| HK40073040B (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| Visser et al. | Hormones and hormone antagonists | |
| Plus | 1 INDICATIONS AND USAGE | |
| HK40014579A (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| HK1232778A (en) | Drospirenone-based contraceptive for a female patient affected with excess weight | |
| HK1232778A1 (en) | Drospirenone-based contraceptive for a female patient affected with excess weight | |
| CN106265694A (zh) | 用于过重女性患者的基于屈螺酮的避孕药 |